Burkitt Lymphoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma defined by a Ki-67 proliferation index approaching 100%, making it the fastest-growing human cancer. It occurs in three clinical variants: endemic (African, EBV-associated in nearly all cases, characteristically presents as jaw or facial mass in children aged 4-7 years); sporadic (Western countries, abdominal presentation predominates, EBV-associated in approximately 30%); and immunodeficiency-related (HIV-associated, often CNS involved). All three variants share the hallmark t(8;14)(q24;q32) MYC-immunoglobulin translocation. Burkitt lymphoma accounts for approximately 30% of all childhood non-Hodgkin lymphomas and 1-2% of adult lymphomas. Urgent treatment initiation — within 24-48 hours of diagnosis — is essential given its extreme proliferative rate. Burkitt Lymphoma: Causes, Symptoms, Diagnosis and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Burkitt Lymphoma: Causes, Symptoms, Diagnosis and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

The t(8;14)(q24;q32) translocation placing MYC under immunoglobulin heavy chain gene control is the universal oncogenic driver of all Burkitt lymphoma variants. Endemic BL: EBV co-infection is present in over 95% of cases; Plasmodium falciparum malaria chronically stimulates B-cell proliferation and impairs immune surveillance, creating a permissive oncogenic environment. Sporadic BL: approximately 30% are EBV-associated; other B-cell activating stimuli are postulated. HIV-associated BL: profound immunosuppression leads to chronic polyclonal B-cell activation and failure of tumor immune surveillance. Secondary MYC rearrangements (partnering with IgL kappa or lambda) account for rare cases. No dietary or environmental factors beyond infectious and immune-related triggers are established.

Endemic Burkitt lymphoma: rapidly enlarging jaw or facial tumor (present in approximately 80% of cases), orbital involvement causing proptosis and vision impairment, and paraplegia from spinal cord compression in some children. Sporadic BL: large abdominal mass involving the ileocecal region (most common site), causing bowel obstruction, nausea, abdominal pain, and ascites; right iliac fossa presentation may mimic appendicitis. B symptoms — drenching night sweats, fever above 38°C, and more than 10% weight loss — occur in approximately 50% of patients. CNS involvement presenting with meningeal lymphoma, cranial nerve palsies, or raised intracranial pressure is found at diagnosis in approximately 15% of cases and requires aggressive intrathecal chemotherapy.

Contrast-enhanced CT thorax, abdomen, and pelvis for initial staging; PET-CT provides superior metabolic staging. Bone marrow trephine biopsy. Lumbar puncture and CSF cytology and flow cytometry are mandatory to assess CNS involvement. Excisional biopsy with flow cytometry demonstrates the characteristic immunophenotype: CD20+, CD10+, BCL6+, BCL2-negative, surface IgM+, Ki-67 approaching 100%. FISH confirmation of t(8;14) MYC translocation is required; variant translocations t(2;8) and t(8;22) also occur. Serum LDH is markedly elevated and is a key prognostic marker. Ann Arbor staging documents CNS, bone marrow, and visceral involvement. Tumor lysis syndrome risk stratification is mandatory before initiating treatment — aggressive pre-hydration and rasburicase are required.

Dose-intensive short-duration immunochemotherapy is the standard approach and must begin urgently. R-CODOX-M/IVAC (Magrath regimen plus rituximab) — alternating CODOX-M (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate) with IVAC (ifosfamide, etoposide, high-dose cytarabine) plus rituximab — is the standard for high-risk adult patients, typically 4 cycles. DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin plus rituximab) is used for lower-risk or elderly patients with less toxicity. CNS prophylaxis with intrathecal methotrexate is integrated throughout every regimen. Aggressive inpatient hydration, allopurinol, and rasburicase prevent fatal tumor lysis syndrome. HIV-positive patients must receive concurrent antiretroviral therapy. Allogeneic stem cell transplantation is not routinely used in first-line treatment.

Burkitt lymphoma has become one of the most curable aggressive cancers with intensive chemotherapy despite its extreme growth rate. In pediatric patients with endemic or sporadic Burkitt lymphoma, intensive short-duration immunochemotherapy achieves event-free survival exceeding 85-90% in low-risk and approximately 75-80% in high-risk disease. Adult patients treated with R-CODOX-M/IVAC achieve complete remission rates of approximately 70-85%, with 3-year PFS of 60-70% overall. CNS-negative low-risk disease (single resected mass, LDH less than 2x normal) achieves 5-year OS exceeding 90%. HIV-associated Burkitt lymphoma treated with concurrent ART and DA-EPOCH-R achieves 2-year OS of approximately 60-70% in virologically controlled patients. Key prognostic factors are CNS involvement at diagnosis (2-year OS reduced to 40-60%), bone marrow involvement, LDH level, performance status, and completeness of response after cycle 1 of chemotherapy. Late relapse beyond 2 years is rare; most relapses occur within 6-12 months of initial treatment. Relapsed or refractory Burkitt lymphoma has very poor prognosis — median OS less than 6 months despite salvage regimens. Long-term survivors require monitoring for late effects of intensive chemotherapy: anthracycline-related cardiomyopathy, peripheral neuropathy from vincristine, and secondary malignancies at 10-20 years. Annual clinical review and echocardiography are recommended for the first 10 years post-therapy.

Endemic Burkitt lymphoma prevention involves malaria control (insecticide-treated bed nets, artemisinin combination therapy) to reduce the immunosuppressive co-factor of Plasmodium falciparum infection in endemic African regions. An effective EBV vaccine would theoretically reduce endemic BL incidence but remains in development. HIV prevention — including HIV testing, antiretroviral therapy for HIV-positive individuals, pre-exposure prophylaxis (PrEP), and safe sex practices — reduces the incidence of HIV-associated Burkitt lymphoma. Optimal antiretroviral control in HIV-positive individuals normalizes immune function and substantially reduces lymphoma risk. Sporadic BL, which affects Western populations without specific infectious triggers, has no established preventive measures. Early diagnosis and urgent treatment remain the primary determinants of outcome.

Given Burkitt lymphoma's tumor doubling time of 24-48 hours, medical evaluation must be sought urgently — not deferred — for any rapidly growing mass. Seek emergency evaluation for: a rapidly enlarging jaw, orbital, or facial swelling in a child (endemic variant); rapidly increasing abdominal mass or distension with nausea and bowel symptoms; unexplained fever, drenching night sweats, and weight loss (B symptoms); sudden onset of neurological symptoms suggesting meningeal involvement; or lymphadenopathy with extremely rapid growth over days. Any individual known to have HIV or significant immunosuppression who develops lymphadenopathy or mass lesions should be evaluated promptly. Burkitt lymphoma is a hematologic emergency — delays in diagnosis and treatment can be fatal within days to weeks.